Search

everythinglearnresearchcommunity

for

Search:↓

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

Ritlecitinib may help young adults with severe alopecia areata when ketoconazole fails.

Ritlecitinib may help young adults with severe alopecia areata when ketoconazole doesn't work.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Nilotinib can cause generalized keratosis pilaris.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.

Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.

CT-707 is effective and safe for treating certain Chinese lung cancer patients.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

The FDA approved a new Pfizer drug for hair loss in teens.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

Nilotinib can cause skin issues like red bumps and hair loss.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Erlotinib can cause significant but temporary hair loss in lung cancer patients.

A man treated with gefitinib for lung cancer grew new hair on his bald scalp.

Aumolertinib effectively controls lung cancer and improves quality of life.

Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

The treatment combination is effective and generally safe for lung cancer.

Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.

CTP-543 is generally safe for treating alopecia areata.